WO2004002986A2 - Novel benzimidazole derivatives - Google Patents

Novel benzimidazole derivatives Download PDF

Info

Publication number
WO2004002986A2
WO2004002986A2 PCT/JP2003/008161 JP0308161W WO2004002986A2 WO 2004002986 A2 WO2004002986 A2 WO 2004002986A2 JP 0308161 W JP0308161 W JP 0308161W WO 2004002986 A2 WO2004002986 A2 WO 2004002986A2
Authority
WO
WIPO (PCT)
Prior art keywords
lower alkyl
halo
hydroxy
methine
group
Prior art date
Application number
PCT/JP2003/008161
Other languages
English (en)
French (fr)
Other versions
WO2004002986A3 (en
Inventor
Norikazu Otake
Minoru Moriya
Yoshio Ogino
Kenji Matsuda
Yoshikazu Nagae
Akio Kanatani
Takehiro Fukami
Original Assignee
Banyu Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2003248248A priority Critical patent/AU2003248248B2/en
Priority to EP03761822A priority patent/EP1517908B1/en
Priority to AT03761822T priority patent/ATE506360T1/de
Priority to YUP-1137/04A priority patent/RS113704A/sr
Application filed by Banyu Pharmaceutical Co., Ltd. filed Critical Banyu Pharmaceutical Co., Ltd.
Priority to BR0312066-0A priority patent/BR0312066A/pt
Priority to CA2490722A priority patent/CA2490722C/en
Priority to DE60336811T priority patent/DE60336811D1/de
Priority to EA200500103A priority patent/EA200500103A1/ru
Priority to MXPA04012731A priority patent/MXPA04012731A/es
Publication of WO2004002986A2 publication Critical patent/WO2004002986A2/en
Publication of WO2004002986A3 publication Critical patent/WO2004002986A3/en
Priority to IL16581004A priority patent/IL165810A0/xx
Priority to HR20041218A priority patent/HRP20041218A2/hr
Priority to NO20050184A priority patent/NO20050184L/no
Priority to IS7667A priority patent/IS7667A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
PCT/JP2003/008161 2002-06-28 2003-06-26 Novel benzimidazole derivatives WO2004002986A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CA2490722A CA2490722C (en) 2002-06-28 2003-06-26 Novel benzimidazole derivatives
AT03761822T ATE506360T1 (de) 2002-06-28 2003-06-26 Neue benzimidazolderivate
YUP-1137/04A RS113704A (en) 2002-06-28 2003-06-26 Novel benzimidazole derivatives
EA200500103A EA200500103A1 (ru) 2002-06-28 2003-06-26 Новые производные бензимидазола
BR0312066-0A BR0312066A (pt) 2002-06-28 2003-06-26 Novos derivados de benzimidazol
EP03761822A EP1517908B1 (en) 2002-06-28 2003-06-26 Novel benzimidazole derivatives
DE60336811T DE60336811D1 (de) 2002-06-28 2003-06-26 Neue benzimidazolderivate
AU2003248248A AU2003248248B2 (en) 2002-06-28 2003-06-26 Novel benzimidazole derivatives
MXPA04012731A MXPA04012731A (es) 2002-06-28 2003-06-26 Novedosos derivados de bencimidazol.
IL16581004A IL165810A0 (en) 2002-06-28 2004-12-16 Novel benzimidazole derivatives
HR20041218A HRP20041218A2 (en) 2002-06-28 2004-12-28 Novel benzimidazole derivatives
NO20050184A NO20050184L (no) 2002-06-28 2005-01-12 Nye benzimidazolderivater
IS7667A IS7667A (is) 2002-06-28 2005-01-27 Nýjar bensimídazólafleiður

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002-190978 2002-06-28
JP2002190978 2002-06-28

Publications (2)

Publication Number Publication Date
WO2004002986A2 true WO2004002986A2 (en) 2004-01-08
WO2004002986A3 WO2004002986A3 (en) 2004-04-22

Family

ID=29996905

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/008161 WO2004002986A2 (en) 2002-06-28 2003-06-26 Novel benzimidazole derivatives

Country Status (23)

Country Link
US (3) US7105526B2 (US20040054177A1-20040318-C00011.png)
EP (1) EP1517908B1 (US20040054177A1-20040318-C00011.png)
CN (2) CN100560585C (US20040054177A1-20040318-C00011.png)
AR (1) AR040271A1 (US20040054177A1-20040318-C00011.png)
AT (1) ATE506360T1 (US20040054177A1-20040318-C00011.png)
AU (1) AU2003248248B2 (US20040054177A1-20040318-C00011.png)
BR (1) BR0312066A (US20040054177A1-20040318-C00011.png)
CA (1) CA2490722C (US20040054177A1-20040318-C00011.png)
DE (1) DE60336811D1 (US20040054177A1-20040318-C00011.png)
DO (1) DOP2003000662A (US20040054177A1-20040318-C00011.png)
EA (1) EA200500103A1 (US20040054177A1-20040318-C00011.png)
EC (1) ECSP045505A (US20040054177A1-20040318-C00011.png)
HR (1) HRP20041218A2 (US20040054177A1-20040318-C00011.png)
IL (1) IL165810A0 (US20040054177A1-20040318-C00011.png)
IS (1) IS7667A (US20040054177A1-20040318-C00011.png)
MX (1) MXPA04012731A (US20040054177A1-20040318-C00011.png)
NO (1) NO20050184L (US20040054177A1-20040318-C00011.png)
PE (1) PE20040583A1 (US20040054177A1-20040318-C00011.png)
PL (1) PL374693A1 (US20040054177A1-20040318-C00011.png)
RS (1) RS113704A (US20040054177A1-20040318-C00011.png)
TW (1) TW200406411A (US20040054177A1-20040318-C00011.png)
WO (1) WO2004002986A2 (US20040054177A1-20040318-C00011.png)
ZA (1) ZA200409339B (US20040054177A1-20040318-C00011.png)

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US7365079B2 (en) * 2002-11-29 2008-04-29 Banyu Pharmaceutical Co., Ltd. Azole derivatives
WO2008120653A1 (ja) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. インドールジオン誘導体
WO2010051236A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
WO2010099527A1 (en) 2009-02-27 2010-09-02 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US7960384B2 (en) 2006-03-28 2011-06-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2011076747A1 (en) * 2009-12-21 2011-06-30 Novartis Ag Diaza-spiro[5.5]undecanes as orexin receptor antagonists
EP2374731A1 (en) 2010-04-07 2011-10-12 Altachem N.V. High performance valve
US8084605B2 (en) 2006-11-29 2011-12-27 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8288405B2 (en) 2009-11-10 2012-10-16 Pfizer Inc. N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
US8318762B2 (en) 2008-05-28 2012-11-27 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
WO2013059222A1 (en) 2011-10-19 2013-04-25 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-nitrile orexin receptor antagonists
EP2698157A1 (en) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US8802688B2 (en) 2011-04-22 2014-08-12 Pfizer Inc. Substituted acetyl-coa carboxylase inhibitors
US8859577B2 (en) 2010-09-30 2014-10-14 Pfizer Inc. N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
US8859773B2 (en) 2010-10-29 2014-10-14 Pfizer Inc. N1/N2-lactam acetyl-CoA carboxylase inhibitors
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
JPWO2013011932A1 (ja) * 2011-07-15 2015-02-23 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有するアザベンズイミダゾール誘導体
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US9708318B2 (en) 2015-02-20 2017-07-18 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9745311B2 (en) 2012-08-10 2017-08-29 Incyte Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9801889B2 (en) 2015-02-20 2017-10-31 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9890156B2 (en) 2015-02-20 2018-02-13 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10040790B2 (en) 2013-04-19 2018-08-07 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10213427B2 (en) 2010-12-22 2019-02-26 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US10611762B2 (en) 2017-05-26 2020-04-07 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
WO2022040070A1 (en) 2020-08-18 2022-02-24 Merck Sharp & Dohme Corp. Bicycloheptane pyrrolidine orexin receptor agonists
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6374762B1 (en) * 1997-10-27 2002-04-23 Correct Craft, Inc. Water sport towing apparatus
JP2006519229A (ja) * 2003-02-13 2006-08-24 アルバート・アインシュタイン・カレッジ・オヴ・メディシン・オヴ・イェシヴァ・ユニヴァーシティ 視床下部内の長鎖脂肪アシルＣｏＡレベルの変調による摂食量およびグルコース産生量の調節
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US20060019954A1 (en) * 2004-07-20 2006-01-26 Cedars-Sinai Medical Center Method for reducing the likelihood of the occurrence of cardiac arrhythmias
US7786141B2 (en) * 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
JP2008510728A (ja) 2004-08-19 2008-04-10 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
WO2006058303A2 (en) * 2004-11-29 2006-06-01 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2006088798A2 (en) * 2005-02-14 2006-08-24 Albert Einstein College Of Medicine Of Yeshiva University Modulation of hypothalamic atp-sensitive potassium channels
US7822474B2 (en) * 2005-11-30 2010-10-26 Cedars-Sinai Medical Center Methods for the prediction of arrhythmias and prevention of sudden cardiac death
WO2007076070A2 (en) * 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
KR20080098070A (ko) * 2006-02-22 2008-11-06 버텍스 파마슈티칼스 인코포레이티드 무스카린성 수용체의 조절제로서의 스피로 축합된 피페리딘
KR20080094964A (ko) * 2006-02-22 2008-10-27 버텍스 파마슈티칼스 인코포레이티드 무스카린성 수용체의 조절제
EP1991547A2 (en) * 2006-03-09 2008-11-19 Pharmacopeia, Inc. 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
JP2009542670A (ja) * 2006-06-29 2009-12-03 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体の調節剤
US8003620B2 (en) * 2006-08-04 2011-08-23 Isis Pharmaceuticals, Inc. Compositions and their uses directed to diacylglycerol acyltransferase 1
AU2007284548A1 (en) * 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
JP2010501561A (ja) 2006-08-18 2010-01-21 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体の調節剤
US7973162B2 (en) * 2007-10-03 2011-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US20090281143A1 (en) * 2007-12-10 2009-11-12 N-Gene Research Laboratories, Inc. Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PE20180800A1 (es) 2015-07-10 2018-05-09 Ionis Pharmaceuticals Inc Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11683717B2 (en) * 2020-11-09 2023-06-20 Celona, Inc. Method and apparatus for determining wireless MNO coverage and efficiently operating an enterprise wireless communication network

Citations (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914250A (en) 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
US4189438A (en) 1977-02-08 1980-02-19 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Physiologically active substance esterastin
US4405644A (en) 1979-07-14 1983-09-20 Bayer Aktiengesellschaft Medicaments for the treatment of disorders of lipometabolism and their use
US4452813A (en) 1981-05-22 1984-06-05 Taiho Pharmaceutical Company Limited Sulfonate derivatives, process for preparing same and antilipemic compositions containing the derivative
EP0136976A2 (de) 1983-08-23 1985-04-10 Ciba-Geigy Ag Verwendung von Phenylpyrimidinen als Pflanzenregulatoren
US4598089A (en) 1983-06-22 1986-07-01 Hoffmann-La Roche Inc. Leucine derivatives
US4746680A (en) 1981-04-06 1988-05-24 The Boots Company P.L.C. Therapeutic agents
US4973587A (en) 1990-03-08 1990-11-27 Sterling Drug Inc. 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method
US5013837A (en) 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
US5081122A (en) 1990-03-05 1992-01-14 Sterling Drug Inc. Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof
US5112820A (en) 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
US5292736A (en) 1993-02-26 1994-03-08 Sterling Winthrop Inc. Morpholinoalkylindenes as antiglaucoma agents
WO1994009134A2 (en) 1992-10-09 1994-04-28 Regeneron Pharmaceuticals, Inc. Modified ciliary neurotrophic factors
US5391571A (en) 1989-11-15 1995-02-21 American Home Products Corporation Cholesterol ester hydrolase inhibitors
EP0658546A1 (fr) 1993-12-17 1995-06-21 Sanofi Dérivés de 3-pyrazolecarboxamide avec une affinité pour le récepteur des cannabinoides
US5436272A (en) 1988-11-29 1995-07-25 The Boots Company (Usa), Inc. Treatment of obesity
US5451677A (en) 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
WO1996014307A1 (en) 1994-11-07 1996-05-17 Pfizer Inc. Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
WO1996016542A1 (en) 1994-12-02 1996-06-06 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5)
US5532237A (en) 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
WO1996023518A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
WO1996023519A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
WO1996023520A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
WO1996023515A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
WO1996023516A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
WO1996023514A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
WO1996023513A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
WO1996033159A1 (en) 1995-04-21 1996-10-24 Abbott Laboratories Cyclobutane derivatives as inhibitors of squalene synthase and protein farnesyltransferase
US5624941A (en) 1992-06-23 1997-04-29 Sanofi Pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present
WO1997019682A1 (en) 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
WO1997020823A2 (en) 1995-12-01 1997-06-12 Novartis Ag 2-amino quinazoline derivatives as npy receptor antagonists
WO1997020820A1 (en) 1995-12-01 1997-06-12 Novartis Ag Heteroaryl compounds
WO1997020821A1 (en) 1995-12-01 1997-06-12 Novartis Ag Heteroaryl derivatives
WO1997020822A1 (en) 1995-12-01 1997-06-12 Novartis Ag Quinazolin-2,4-diazirines as npy receptor antagonist
WO1997029079A1 (fr) 1996-02-06 1997-08-14 Japan Tobacco Inc. Composes chimiques et utilisation pharmaceutique
US5705515A (en) 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
US5739106A (en) 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
WO1998022128A1 (en) 1996-11-19 1998-05-28 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Use of cntf (ciliary neurotrophic factor) receptor activators for the treatment of obesity
WO1998027063A1 (fr) 1996-12-16 1998-06-25 Banyu Pharmaceutical Co., Ltd. Derives d'aminopyrazole
WO1998031227A1 (en) 1997-01-21 1998-07-23 Smithkline Beecham Corporation Novel cannabinoid receptor modulators
WO1998033765A1 (en) 1997-02-04 1998-08-06 E.I. Du Pont De Nemours And Company Fungicidal carboxamides
WO1998037061A1 (de) 1997-02-21 1998-08-27 Bayer Aktiengesellschaft Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
WO1998041519A1 (en) 1997-03-18 1998-09-24 Smithkline Beecham Corporation Novel cannabinoid receptor agonists
WO1998043636A1 (fr) 1997-03-28 1998-10-08 Sanofi-Synthelabo Composition pharmaceutique pour administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs s olvates
WO1998043635A1 (fr) 1997-03-28 1998-10-08 Sanofi-Synthelabo Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino- 3-pyrazolecarboxamide, de ses sels et de leurs solvates
WO1999000123A1 (en) 1997-06-26 1999-01-07 Pharmacia & Upjohn Ab Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity
WO1999002499A1 (fr) 1997-07-11 1999-01-21 Japan Tobacco Inc. Composes quinoline et utilisations de ceux-ci en medecine
WO1999027965A1 (fr) 1997-11-28 1999-06-10 Banyu Pharmaceutical Co., Ltd. Agents anti-hyperlipemiques
WO1999043813A1 (en) 1998-02-27 1999-09-02 Regeneron Pharmaceuticals, Inc. Modified ciliary neurotrophic factor, method of making and methods of use thereof
WO1999051600A1 (en) 1998-04-02 1999-10-14 Neurogen Corporation AMINOALKYL SUBSTITUTED 9H-PYRIDINO[2,3-b]INDOLE AND 9H-PYRIMIDINO[4,5-b]INDOLE DERIVATIVES
US6001836A (en) 1997-05-28 1999-12-14 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: cyanoguanidine derivatives
WO1999064002A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
US6028084A (en) 1995-11-23 2000-02-22 Sanofi-Synthelabo Pyrazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives
WO2000010967A1 (de) 1998-08-19 2000-03-02 Bayer Aktiengesellschaft Neue arylsulfonamide und analoga
WO2000010968A2 (de) 1998-08-19 2000-03-02 Bayer Aktiengesellschaft Neue aminosäureester von arylsulfonamiden und analoga
WO2000021509A2 (en) 1998-10-15 2000-04-20 Imperial College Innovations Limited Methods of treatment
WO2000027845A1 (en) 1998-11-10 2000-05-18 Merck & Co., Inc. Spiro-indolines as y5 receptor antagonists
EP1010691A2 (fr) 1998-12-17 2000-06-21 Adir Et Compagnie Dérives de l'hydrazide, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
JP2000256190A (ja) 1999-03-01 2000-09-19 Pfizer Prod Inc 甲状腺類似の抗肥満薬
EP1044970A1 (fr) 1999-04-15 2000-10-18 Adir Et Compagnie Nouveaux composés aminotriazoles, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
US6140354A (en) 1998-04-29 2000-10-31 Ortho-Mcneil Pharmaceutical, Inc. N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
WO2000064880A1 (en) 1999-04-22 2000-11-02 Synaptic Pharmaceutical Corporation Selective npy (y5) antagonists
WO2000068197A1 (en) 1999-05-05 2000-11-16 Ortho-Mcneil Pharmaceutical, Inc. 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS
WO2000069849A1 (en) 1999-05-12 2000-11-23 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
WO2000074679A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
WO2001002379A1 (en) 1999-06-30 2001-01-11 Synaptic Pharmaceutical Corporation Selective npy (y5) antagonists
WO2001007409A1 (en) 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
WO2001009120A1 (en) 1999-07-28 2001-02-08 Ortho-Mcneil Pharmaceutical, Inc. Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
WO2001014376A1 (en) 1999-08-20 2001-03-01 Banyu Pharmaceutical Co., Ltd. Novel spiro compounds
WO2001023388A2 (en) 1999-09-30 2001-04-05 Neurogen Corporation AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES
WO2001023389A2 (en) 1999-09-30 2001-04-05 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
WO2001023387A2 (en) 1999-09-30 2001-04-05 Neurogen Corporation CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES
WO2001027068A1 (en) 1999-10-13 2001-04-19 Pfizer Products Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors
WO2001027060A1 (de) 1999-10-13 2001-04-19 Haarmann & Reimer Gmbh Verfahren zur herstellung von arylalkylethern
WO2001044201A1 (en) 1999-12-16 2001-06-21 Schering Corporation Substituted imidazole neuropeptide y y5 receptor antagonists
US6258837B1 (en) 1997-04-23 2001-07-10 Banyu Pharmaceutical Co., Ltd. Neuropeptide Y receptor antagonist
WO2001056592A1 (en) 2000-02-01 2001-08-09 Novo Nordisk A/S Use of compounds for the regulation of food intake
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
JP2001226269A (ja) 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
WO2001062738A1 (fr) 2000-02-22 2001-08-30 Banyu Pharmaceutical Co., Ltd. Composes a base d'imidazoline
WO2001062341A2 (en) 2000-02-22 2001-08-30 Knoll Gmbh Combination product for the treatment of obesity
WO2001062737A2 (en) 2000-02-24 2001-08-30 Ortho-Mcneil Pharmaceutical, Inc. Amino pyrazole derivatives useful for the treatment of obesity and other disorders
WO2001064632A1 (fr) 2000-03-03 2001-09-07 Aventis Pharma S.A. Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
WO2001064633A1 (fr) 2000-03-03 2001-09-07 Aventis Pharma S.A. Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation
WO2001064634A1 (fr) 2000-03-03 2001-09-07 Aventis Pharma S.A. Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
WO2001066548A1 (en) 2000-03-06 2001-09-13 F. Hoffmann-La Roche Ag New aza-indolyl derivatives
WO2001068609A1 (en) 2000-03-14 2001-09-20 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivatives
WO2001070337A1 (en) 2000-03-23 2001-09-27 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
WO2001070708A1 (en) 2000-03-23 2001-09-27 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
WO2001074782A1 (en) 2001-03-29 2001-10-11 Molecular Design International, Inc. β3-ADRENORECEPTOR AGONISTS, AGONIST COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
WO2001074844A2 (en) 2000-04-04 2001-10-11 F. Hoffmann-La Roche Ag Selective linear peptides with melanocortin-4 receptor (mc4-r) agonist activity
WO2001077094A1 (en) 2000-04-07 2001-10-18 Aventis Pharma Deutschland Gmbh Percyquinnin, a process for its production and its use as a pharmaceutical
WO2001082925A1 (fr) 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Antagonistes de l'hormone concentrant la melanine
WO2001085730A1 (en) 2000-05-09 2001-11-15 Astrazeneca Ab Pyrido' 1,2-alpha pyrazine and piperidine derivatives as ligands for the neuropeptide y y5 receptor
WO2001085098A2 (en) 2000-05-10 2001-11-15 Bristol-Myers Squibb Company Squarate derivatives of dihydropyridine npy antagonists
WO2001085714A1 (en) 2000-05-05 2001-11-15 Astrazeneca Ab Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by the np y5 receptor
WO2001085690A1 (en) 2000-05-10 2001-11-15 Bristol-Myers Squibb Company 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine npy antagonists
WO2001085173A1 (en) 2000-05-10 2001-11-15 Bristol-Myers Squibb Company Alkylamine derivatives of dihydropyridine npy antagonists
WO2001087335A2 (en) 2000-05-17 2001-11-22 Eli Lilly And Company Method for selectively inhibiting ghrelin action
WO2001087834A1 (fr) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
WO2001089528A1 (en) 2000-05-19 2001-11-29 Bristol-Myers Squibb Company Thiourea derivatives of dihydropyridine npy antagonists
WO2001090092A1 (en) 2000-05-22 2001-11-29 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2001091752A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
US6329395B1 (en) 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
WO2001096330A2 (en) 2000-06-15 2001-12-20 Schering Corporation Thrombin receptor antagonists
WO2001096302A1 (en) 2000-06-16 2001-12-20 Smithkline Beecham P.L.C. Piperidines for use as orexin receptor antagonists
US6337332B1 (en) 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
WO2002004433A2 (en) 2000-07-06 2002-01-17 Neurogen Corporation Melanin concentrating hormone receptor ligands
US20020006964A1 (en) 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
WO2002006245A1 (en) 2000-07-05 2002-01-24 Synaptic Pharmarceutical Corporation Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof
WO2002008250A2 (en) 2000-07-24 2002-01-31 Ardana Bioscience Limited Ghrelin antagonists
WO2002010169A1 (en) 2000-07-31 2002-02-07 F. Hoffmann-La Roche Ag Piperazine derivatives
WO2002012166A2 (en) 2000-08-04 2002-02-14 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
WO2002012178A1 (en) 2000-08-07 2002-02-14 Melacure Therapeutics Ab Compounds acting as melanocortin receptor ligands
WO2002011715A2 (en) 2000-08-07 2002-02-14 Melacure Therapeutics Ab The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands
US20020022637A1 (en) 2000-05-11 2002-02-21 Li James J. Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
WO2002015905A1 (en) 2000-08-21 2002-02-28 Gliatech, Inc. The use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity
WO2002015845A2 (en) 2000-08-21 2002-02-28 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
WO2002015909A1 (en) 2000-08-23 2002-02-28 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
WO2002020488A2 (en) 2000-09-06 2002-03-14 F. Hoffmann-La Roche Ag Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor
US6358951B1 (en) 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
WO2002022592A2 (en) 2000-09-14 2002-03-21 Schering Corporation Substituted urea neuropeptide y y5 receptor antagonists
US6365633B1 (en) 1999-03-19 2002-04-02 Knoll Pharmaceutical Company Method of treating eating disorders
WO2002032897A1 (en) 2000-10-20 2002-04-25 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
WO2002032888A1 (en) 2000-10-13 2002-04-25 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
US20020049196A1 (en) 1995-12-28 2002-04-25 Carpino Philip A. Growth-hormone secretagogues
WO2002036596A2 (en) 2000-11-03 2002-05-10 Wyeth CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES
WO2002040456A1 (en) 2000-11-20 2002-05-23 Biovitrum Ab Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor
WO2002040457A1 (en) 2000-11-20 2002-05-23 Biovitrum Ab Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
WO2002044152A1 (en) 2000-10-16 2002-06-06 F. Hoffmann-La Roche Ag Indoline derivatives and their use as 5-ht2 receptor ligands
WO2002048152A2 (en) 2000-12-12 2002-06-20 Neurogen Corporation Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
WO2002048124A2 (en) 2000-12-15 2002-06-20 F. Hoffmann-La Roche Ag Piperazine derivatives
WO2002049648A1 (en) 2000-12-21 2002-06-27 Schering Corporation Heteroaryl urea neuropeptide y y5 receptor antagonists
WO2002051844A1 (en) 2000-12-27 2002-07-04 F. Hoffmann-La Roche Ag Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands
WO2002051838A1 (en) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
WO2002051809A1 (en) 2000-12-22 2002-07-04 Schering Corporation Piperidine mch antagonists and their use in the treatment of obesity
WO2002059117A1 (en) 2001-01-23 2002-08-01 Eli Lilly And Company Piperazine- and piperidine-derivatives as melanocortin receptor agonists
WO2002059107A1 (en) 2001-01-23 2002-08-01 Eli Lilly And Company Substituted piperidines/piperazines as melanocortin receptor agonists
WO2002059095A1 (en) 2001-01-23 2002-08-01 Eli Lilly And Company Melanocortin receptor agonists
WO2002062764A1 (en) 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Fused heterocyclic compounds
WO2002068387A2 (en) 2001-02-28 2002-09-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2002067869A2 (en) 2001-02-28 2002-09-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2002068388A2 (en) 2001-02-28 2002-09-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2002076947A1 (en) 2001-03-21 2002-10-03 Schering Corporation Mch antagonists and their use in the treatment of obesity
WO2002076949A1 (en) 2001-03-22 2002-10-03 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
WO2002076929A1 (en) 2001-03-21 2002-10-03 Pharmacopeia, Inc. Aryl and biaryl compounds having mch modulatory activity
WO2002083128A1 (en) 2001-04-12 2002-10-24 Bristol-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method
WO2002083134A1 (en) 2001-04-12 2002-10-24 Pharmacopeia, Inc. Aryl and biaryl piperidines used as mch antagonists
EP1258476A1 (fr) 2001-05-15 2002-11-20 Les Laboratoires Servier Dérivés d'alpha-amino-acides, leur procédé de préparation ainsi que leur utilisation en tant qu'inhibiteurs de dipeptidyl-peptidase IV (DPP IV)
WO2002094789A1 (en) 2001-05-21 2002-11-28 F. Hoffmann-La Roche Ag Quinoline derivatives as ligands for the neuropeptide y receptor
WO2002094799A2 (en) 2001-05-22 2002-11-28 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
WO2003000250A1 (en) 2001-06-25 2003-01-03 Ferring Bv 3-fluoro-pyrrolidines as antidiabetic agents
WO2003000181A2 (en) 2001-06-20 2003-01-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
WO2003000180A2 (en) 2001-06-20 2003-01-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
WO2003002530A2 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors
WO2003002553A2 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
WO2003002593A2 (en) 2001-06-27 2003-01-09 Probiodrug Ag Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis
WO2003002531A2 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
WO2003004027A1 (en) 2001-07-05 2003-01-16 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as mch selective antagonists
WO2003004498A1 (en) 2001-07-06 2003-01-16 Merck & Co., Inc. Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2003004496A1 (en) 2001-07-03 2003-01-16 Novo Nordisk A/S Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
WO2003006007A1 (en) 2001-07-11 2003-01-23 Research & Innovation Soc.Coop. A R.L. Use of compounds as functional antagonists to the central cannabinoid receptors
WO2003007949A1 (en) 2001-07-18 2003-01-30 Merck & Co., Inc. Bridged piperidine derivatives as melanocortin receptor agonists
WO2003007887A2 (en) 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
WO2003009847A1 (en) 2001-07-25 2003-02-06 Amgem, Inc. Substituted piperidines as modulators of the melanocortin receptor
WO2003023561A2 (en) 2001-09-12 2003-03-20 Rockwell Automation Technologies, Inc. Network independent safety protocol for industrial controller using data manipulation techniques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE433971T1 (de) * 2002-11-29 2009-07-15 Banyu Pharma Co Ltd Neue azolderivate

Patent Citations (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914250A (en) 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
US4189438A (en) 1977-02-08 1980-02-19 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Physiologically active substance esterastin
US4242453A (en) 1977-02-08 1980-12-30 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Cultivating streptomyces to produce an esterase inhibitor
US4405644A (en) 1979-07-14 1983-09-20 Bayer Aktiengesellschaft Medicaments for the treatment of disorders of lipometabolism and their use
US4746680A (en) 1981-04-06 1988-05-24 The Boots Company P.L.C. Therapeutic agents
US4806570A (en) 1981-04-06 1989-02-21 The Boots Company Plc Therapeutic agents
US4452813A (en) 1981-05-22 1984-06-05 Taiho Pharmaceutical Company Limited Sulfonate derivatives, process for preparing same and antilipemic compositions containing the derivative
US4598089A (en) 1983-06-22 1986-07-01 Hoffmann-La Roche Inc. Leucine derivatives
EP0136976A2 (de) 1983-08-23 1985-04-10 Ciba-Geigy Ag Verwendung von Phenylpyrimidinen als Pflanzenregulatoren
US5436272A (en) 1988-11-29 1995-07-25 The Boots Company (Usa), Inc. Treatment of obesity
US5391571A (en) 1989-11-15 1995-02-21 American Home Products Corporation Cholesterol ester hydrolase inhibitors
US5512565A (en) 1989-11-15 1996-04-30 American Home Products Corporation Cholesterol ester hydrolase inhibitors
US5602151A (en) 1989-11-15 1997-02-11 American Home Products Corporation Cholesterol ester hydrolase inhibitors
US5112820A (en) 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
US5081122A (en) 1990-03-05 1992-01-14 Sterling Drug Inc. Antiglaucoma compositions containing 4-arylcarbonyl-1-(4-morpholinyl)-lower-alkyl)-1H-indoles and method of use thereof
US5013837A (en) 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
US4973587A (en) 1990-03-08 1990-11-27 Sterling Drug Inc. 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method
US5624941A (en) 1992-06-23 1997-04-29 Sanofi Pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present
WO1994009134A2 (en) 1992-10-09 1994-04-28 Regeneron Pharmaceuticals, Inc. Modified ciliary neurotrophic factors
US5451677A (en) 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
US5292736A (en) 1993-02-26 1994-03-08 Sterling Winthrop Inc. Morpholinoalkylindenes as antiglaucoma agents
EP0658546A1 (fr) 1993-12-17 1995-06-21 Sanofi Dérivés de 3-pyrazolecarboxamide avec une affinité pour le récepteur des cannabinoides
US5705515A (en) 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
WO1996014307A1 (en) 1994-11-07 1996-05-17 Pfizer Inc. Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands
WO1996016542A1 (en) 1994-12-02 1996-06-06 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5)
WO1996023520A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
WO1996023518A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
WO1996023515A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
WO1996023516A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
WO1996023517A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
WO1996023514A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
WO1996023513A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
WO1996023519A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
US5532237A (en) 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
WO1996033159A1 (en) 1995-04-21 1996-10-24 Abbott Laboratories Cyclobutane derivatives as inhibitors of squalene synthase and protein farnesyltransferase
US20020006964A1 (en) 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
US5739106A (en) 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US6028084A (en) 1995-11-23 2000-02-22 Sanofi-Synthelabo Pyrazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives
WO1997020821A1 (en) 1995-12-01 1997-06-12 Novartis Ag Heteroaryl derivatives
WO1997020822A1 (en) 1995-12-01 1997-06-12 Novartis Ag Quinazolin-2,4-diazirines as npy receptor antagonist
WO1997019682A1 (en) 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
WO1997020820A1 (en) 1995-12-01 1997-06-12 Novartis Ag Heteroaryl compounds
WO1997020823A2 (en) 1995-12-01 1997-06-12 Novartis Ag 2-amino quinazoline derivatives as npy receptor antagonists
US20020049196A1 (en) 1995-12-28 2002-04-25 Carpino Philip A. Growth-hormone secretagogues
WO1997029079A1 (fr) 1996-02-06 1997-08-14 Japan Tobacco Inc. Composes chimiques et utilisation pharmaceutique
WO1998022128A1 (en) 1996-11-19 1998-05-28 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Use of cntf (ciliary neurotrophic factor) receptor activators for the treatment of obesity
WO1998027063A1 (fr) 1996-12-16 1998-06-25 Banyu Pharmaceutical Co., Ltd. Derives d'aminopyrazole
WO1998031227A1 (en) 1997-01-21 1998-07-23 Smithkline Beecham Corporation Novel cannabinoid receptor modulators
WO1998033765A1 (en) 1997-02-04 1998-08-06 E.I. Du Pont De Nemours And Company Fungicidal carboxamides
WO1998037061A1 (de) 1997-02-21 1998-08-27 Bayer Aktiengesellschaft Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
WO1998041519A1 (en) 1997-03-18 1998-09-24 Smithkline Beecham Corporation Novel cannabinoid receptor agonists
WO1998043636A1 (fr) 1997-03-28 1998-10-08 Sanofi-Synthelabo Composition pharmaceutique pour administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs s olvates
WO1998043635A1 (fr) 1997-03-28 1998-10-08 Sanofi-Synthelabo Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino- 3-pyrazolecarboxamide, de ses sels et de leurs solvates
US6258837B1 (en) 1997-04-23 2001-07-10 Banyu Pharmaceutical Co., Ltd. Neuropeptide Y receptor antagonist
US6001836A (en) 1997-05-28 1999-12-14 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: cyanoguanidine derivatives
WO1999000123A1 (en) 1997-06-26 1999-01-07 Pharmacia & Upjohn Ab Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity
WO1999002499A1 (fr) 1997-07-11 1999-01-21 Japan Tobacco Inc. Composes quinoline et utilisations de ceux-ci en medecine
WO1999027965A1 (fr) 1997-11-28 1999-06-10 Banyu Pharmaceutical Co., Ltd. Agents anti-hyperlipemiques
WO1999043813A1 (en) 1998-02-27 1999-09-02 Regeneron Pharmaceuticals, Inc. Modified ciliary neurotrophic factor, method of making and methods of use thereof
WO1999051600A1 (en) 1998-04-02 1999-10-14 Neurogen Corporation AMINOALKYL SUBSTITUTED 9H-PYRIDINO[2,3-b]INDOLE AND 9H-PYRIMIDINO[4,5-b]INDOLE DERIVATIVES
US6140354A (en) 1998-04-29 2000-10-31 Ortho-Mcneil Pharmaceutical, Inc. N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
US6329395B1 (en) 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
WO1999064002A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
WO2000010967A1 (de) 1998-08-19 2000-03-02 Bayer Aktiengesellschaft Neue arylsulfonamide und analoga
WO2000010968A2 (de) 1998-08-19 2000-03-02 Bayer Aktiengesellschaft Neue aminosäureester von arylsulfonamiden und analoga
US6358951B1 (en) 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
US6337332B1 (en) 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
WO2000021509A2 (en) 1998-10-15 2000-04-20 Imperial College Innovations Limited Methods of treatment
US6191160B1 (en) 1998-11-10 2001-02-20 Merck & Co., Inc. Spiro-indolines as Y5 receptor antagonists
WO2000027845A1 (en) 1998-11-10 2000-05-18 Merck & Co., Inc. Spiro-indolines as y5 receptor antagonists
US6313298B1 (en) 1998-11-10 2001-11-06 Merck & Co., Inc. Spiro-indolines as Y5 receptor antagonists
EP1010691A2 (fr) 1998-12-17 2000-06-21 Adir Et Compagnie Dérives de l'hydrazide, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
JP2000256190A (ja) 1999-03-01 2000-09-19 Pfizer Prod Inc 甲状腺類似の抗肥満薬
US6365633B1 (en) 1999-03-19 2002-04-02 Knoll Pharmaceutical Company Method of treating eating disorders
EP1044970A1 (fr) 1999-04-15 2000-10-18 Adir Et Compagnie Nouveaux composés aminotriazoles, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
WO2000064880A1 (en) 1999-04-22 2000-11-02 Synaptic Pharmaceutical Corporation Selective npy (y5) antagonists
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
WO2000068197A1 (en) 1999-05-05 2000-11-16 Ortho-Mcneil Pharmaceutical, Inc. 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS
WO2000069849A1 (en) 1999-05-12 2000-11-23 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
WO2000074679A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
WO2001002379A1 (en) 1999-06-30 2001-01-11 Synaptic Pharmaceutical Corporation Selective npy (y5) antagonists
WO2001007409A1 (en) 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
WO2001009120A1 (en) 1999-07-28 2001-02-08 Ortho-Mcneil Pharmaceutical, Inc. Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
WO2001014376A1 (en) 1999-08-20 2001-03-01 Banyu Pharmaceutical Co., Ltd. Novel spiro compounds
US6326375B1 (en) 1999-08-20 2001-12-04 Banyu Pharmaceutical Co., Ltd. Spiro compounds
US6335345B1 (en) 1999-08-20 2002-01-01 Banyu Pharmaceutical Co., Ltd. Spiro compounds
WO2001023388A2 (en) 1999-09-30 2001-04-05 Neurogen Corporation AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES
WO2001023389A2 (en) 1999-09-30 2001-04-05 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
WO2001023387A2 (en) 1999-09-30 2001-04-05 Neurogen Corporation CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES
WO2001027060A1 (de) 1999-10-13 2001-04-19 Haarmann & Reimer Gmbh Verfahren zur herstellung von arylalkylethern
WO2001027068A1 (en) 1999-10-13 2001-04-19 Pfizer Products Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors
WO2001044201A1 (en) 1999-12-16 2001-06-21 Schering Corporation Substituted imidazole neuropeptide y y5 receptor antagonists
WO2001056592A1 (en) 2000-02-01 2001-08-09 Novo Nordisk A/S Use of compounds for the regulation of food intake
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
JP2001226269A (ja) 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
WO2001062341A2 (en) 2000-02-22 2001-08-30 Knoll Gmbh Combination product for the treatment of obesity
WO2001062738A1 (fr) 2000-02-22 2001-08-30 Banyu Pharmaceutical Co., Ltd. Composes a base d'imidazoline
WO2001062737A2 (en) 2000-02-24 2001-08-30 Ortho-Mcneil Pharmaceutical, Inc. Amino pyrazole derivatives useful for the treatment of obesity and other disorders
WO2001064632A1 (fr) 2000-03-03 2001-09-07 Aventis Pharma S.A. Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
WO2001064634A1 (fr) 2000-03-03 2001-09-07 Aventis Pharma S.A. Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
WO2001064633A1 (fr) 2000-03-03 2001-09-07 Aventis Pharma S.A. Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation
WO2001066548A1 (en) 2000-03-06 2001-09-13 F. Hoffmann-La Roche Ag New aza-indolyl derivatives
WO2001068609A1 (en) 2000-03-14 2001-09-20 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivatives
WO2001070337A1 (en) 2000-03-23 2001-09-27 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
WO2001070708A1 (en) 2000-03-23 2001-09-27 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
WO2001074844A2 (en) 2000-04-04 2001-10-11 F. Hoffmann-La Roche Ag Selective linear peptides with melanocortin-4 receptor (mc4-r) agonist activity
WO2001077094A1 (en) 2000-04-07 2001-10-18 Aventis Pharma Deutschland Gmbh Percyquinnin, a process for its production and its use as a pharmaceutical
WO2001082925A1 (fr) 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Antagonistes de l'hormone concentrant la melanine
WO2001085714A1 (en) 2000-05-05 2001-11-15 Astrazeneca Ab Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by the np y5 receptor
WO2001085730A1 (en) 2000-05-09 2001-11-15 Astrazeneca Ab Pyrido' 1,2-alpha pyrazine and piperidine derivatives as ligands for the neuropeptide y y5 receptor
WO2001085690A1 (en) 2000-05-10 2001-11-15 Bristol-Myers Squibb Company 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine npy antagonists
WO2001085173A1 (en) 2000-05-10 2001-11-15 Bristol-Myers Squibb Company Alkylamine derivatives of dihydropyridine npy antagonists
WO2001085098A2 (en) 2000-05-10 2001-11-15 Bristol-Myers Squibb Company Squarate derivatives of dihydropyridine npy antagonists
US20020022637A1 (en) 2000-05-11 2002-02-21 Li James J. Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
WO2001087834A1 (fr) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
WO2001087335A2 (en) 2000-05-17 2001-11-22 Eli Lilly And Company Method for selectively inhibiting ghrelin action
WO2001089528A1 (en) 2000-05-19 2001-11-29 Bristol-Myers Squibb Company Thiourea derivatives of dihydropyridine npy antagonists
WO2001090091A1 (en) 2000-05-22 2001-11-29 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2001090092A1 (en) 2000-05-22 2001-11-29 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2001090090A1 (en) 2000-05-22 2001-11-29 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2001091752A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
WO2001096330A2 (en) 2000-06-15 2001-12-20 Schering Corporation Thrombin receptor antagonists
WO2001096302A1 (en) 2000-06-16 2001-12-20 Smithkline Beecham P.L.C. Piperidines for use as orexin receptor antagonists
WO2002006245A1 (en) 2000-07-05 2002-01-24 Synaptic Pharmarceutical Corporation Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof
WO2002004433A2 (en) 2000-07-06 2002-01-17 Neurogen Corporation Melanin concentrating hormone receptor ligands
WO2002008250A2 (en) 2000-07-24 2002-01-31 Ardana Bioscience Limited Ghrelin antagonists
WO2002010169A1 (en) 2000-07-31 2002-02-07 F. Hoffmann-La Roche Ag Piperazine derivatives
WO2002012166A2 (en) 2000-08-04 2002-02-14 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
WO2002012178A1 (en) 2000-08-07 2002-02-14 Melacure Therapeutics Ab Compounds acting as melanocortin receptor ligands
WO2002011715A2 (en) 2000-08-07 2002-02-14 Melacure Therapeutics Ab The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands
WO2002015905A1 (en) 2000-08-21 2002-02-28 Gliatech, Inc. The use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity
WO2002015845A2 (en) 2000-08-21 2002-02-28 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
WO2002015909A1 (en) 2000-08-23 2002-02-28 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
WO2002020488A2 (en) 2000-09-06 2002-03-14 F. Hoffmann-La Roche Ag Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor
WO2002022592A2 (en) 2000-09-14 2002-03-21 Schering Corporation Substituted urea neuropeptide y y5 receptor antagonists
WO2002032888A1 (en) 2000-10-13 2002-04-25 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
WO2002044152A1 (en) 2000-10-16 2002-06-06 F. Hoffmann-La Roche Ag Indoline derivatives and their use as 5-ht2 receptor ligands
WO2002032897A1 (en) 2000-10-20 2002-04-25 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
WO2002036596A2 (en) 2000-11-03 2002-05-10 Wyeth CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES
WO2002040456A1 (en) 2000-11-20 2002-05-23 Biovitrum Ab Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor
WO2002040457A1 (en) 2000-11-20 2002-05-23 Biovitrum Ab Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
WO2002048152A2 (en) 2000-12-12 2002-06-20 Neurogen Corporation Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
WO2002048124A2 (en) 2000-12-15 2002-06-20 F. Hoffmann-La Roche Ag Piperazine derivatives
WO2002049648A1 (en) 2000-12-21 2002-06-27 Schering Corporation Heteroaryl urea neuropeptide y y5 receptor antagonists
WO2002051809A1 (en) 2000-12-22 2002-07-04 Schering Corporation Piperidine mch antagonists and their use in the treatment of obesity
WO2002051844A1 (en) 2000-12-27 2002-07-04 F. Hoffmann-La Roche Ag Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands
WO2002051838A1 (en) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
WO2002051232A2 (en) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
WO2002059107A1 (en) 2001-01-23 2002-08-01 Eli Lilly And Company Substituted piperidines/piperazines as melanocortin receptor agonists
WO2002059117A1 (en) 2001-01-23 2002-08-01 Eli Lilly And Company Piperazine- and piperidine-derivatives as melanocortin receptor agonists
WO2002059108A1 (en) 2001-01-23 2002-08-01 Eli Lilly And Company Melanocortin receptor agonists
WO2002059095A1 (en) 2001-01-23 2002-08-01 Eli Lilly And Company Melanocortin receptor agonists
WO2002062764A1 (en) 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Fused heterocyclic compounds
WO2002068387A2 (en) 2001-02-28 2002-09-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2002067869A2 (en) 2001-02-28 2002-09-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2002068388A2 (en) 2001-02-28 2002-09-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2002076947A1 (en) 2001-03-21 2002-10-03 Schering Corporation Mch antagonists and their use in the treatment of obesity
WO2002076929A1 (en) 2001-03-21 2002-10-03 Pharmacopeia, Inc. Aryl and biaryl compounds having mch modulatory activity
WO2002076949A1 (en) 2001-03-22 2002-10-03 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
WO2001074782A1 (en) 2001-03-29 2001-10-11 Molecular Design International, Inc. β3-ADRENORECEPTOR AGONISTS, AGONIST COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
WO2002083128A1 (en) 2001-04-12 2002-10-24 Bristol-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method
WO2002083134A1 (en) 2001-04-12 2002-10-24 Pharmacopeia, Inc. Aryl and biaryl piperidines used as mch antagonists
EP1258476A1 (fr) 2001-05-15 2002-11-20 Les Laboratoires Servier Dérivés d'alpha-amino-acides, leur procédé de préparation ainsi que leur utilisation en tant qu'inhibiteurs de dipeptidyl-peptidase IV (DPP IV)
WO2002094789A1 (en) 2001-05-21 2002-11-28 F. Hoffmann-La Roche Ag Quinoline derivatives as ligands for the neuropeptide y receptor
WO2002094799A2 (en) 2001-05-22 2002-11-28 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
WO2003000181A2 (en) 2001-06-20 2003-01-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
WO2003000180A2 (en) 2001-06-20 2003-01-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
WO2003000250A1 (en) 2001-06-25 2003-01-03 Ferring Bv 3-fluoro-pyrrolidines as antidiabetic agents
WO2003002553A2 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
WO2003002530A2 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors
WO2003002593A2 (en) 2001-06-27 2003-01-09 Probiodrug Ag Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis
WO2003002531A2 (en) 2001-06-27 2003-01-09 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
WO2003004496A1 (en) 2001-07-03 2003-01-16 Novo Nordisk A/S Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
WO2003004027A1 (en) 2001-07-05 2003-01-16 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as mch selective antagonists
WO2003004498A1 (en) 2001-07-06 2003-01-16 Merck & Co., Inc. Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2003006007A1 (en) 2001-07-11 2003-01-23 Research & Innovation Soc.Coop. A R.L. Use of compounds as functional antagonists to the central cannabinoid receptors
WO2003007949A1 (en) 2001-07-18 2003-01-30 Merck & Co., Inc. Bridged piperidine derivatives as melanocortin receptor agonists
WO2003007887A2 (en) 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
WO2003009847A1 (en) 2001-07-25 2003-02-06 Amgem, Inc. Substituted piperidines as modulators of the melanocortin receptor
WO2003023561A2 (en) 2001-09-12 2003-03-20 Rockwell Automation Technologies, Inc. Network independent safety protocol for industrial controller using data manipulation techniques

Non-Patent Citations (53)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF PHYSIOLOGY, vol. 277, 1999, pages R1428
BRAIN RESEARCH, vol. 503, 1989, pages 73
BRAIN RESEARCH, vol. 859, 2000, pages 361
BRITISH JOURNAL OF PHARMACOLOGY, vol. 100, 1990, pages 190
BRITISH JOURNAL OF PHARMACOLOGY, vol. 101, 1990, pages 247
BRITISH JOURNAL OF PHARMACOLOGY, vol. 102, 1991, pages 41
BRITISH JOURNAL OF PHARMACOLOGY, vol. 120, 1998, pages 1335
BRITISH JOURNAL OF PHARMACOLOGY, vol. 95, 1988, pages 419
DEL MAR-GRASA, M. ET AL., OBESITY RESEARCH, vol. 9, 2001, pages 202 - 9
DRUGS, vol. 52, 1996, pages 371
E.S. FORD ET AL., JAMA, vol. 287, no. 3, 16 January 2002 (2002-01-16), pages 356 - 359
ENDOCRINOLOGY, vol. 131, 1992, pages 1970
ENDOCRINOLOGY, vol. 131, 1992, pages 2090
ENDOCRINOLOGY, vol. 133, 1993, pages 1753
ENDOCRINOLOGY, vol. 137, 1996, pages 3177
ENDOCRINOLOGY, vol. 139, 1998, pages 3018
ENDOCRINOLOGY, vol. 140, 1999, pages 5171
ENDOCRINOLOGY, vol. 141, 2000, pages 1011
FEBSLETTERS, vol. 362, 1995, pages 192
GASTROENTEROLOGY, vol. 85, 1983, pages 1411
INTERNATIONAL JOUNAL OF OBESITY, vol. 19, 1995, pages 517
JOURNAL OF AMERICAN CHEMICAL SOCIETY, vol. 78, 1956, pages 1434 - 1437
KIEC-KONONOWICZ, K. ET AL., PHARMAZIE, vol. 55, 2000, pages 349 - 55
LAZEWSKA, D. ET AL., PHARMAZIE, vol. 56, 2001, pages 927 - 32
LIFE SCIENCE, vol. 50, 1992, pages L7
LIFE SCIENCE, vol. 55, 1994, pages 551
NATURE MEDICINE, vol. 3, 1997, pages 761
NATURE MEDICINE, vol. 4, 1998, pages 722
NATURE, vol. 259, 1993, pages 528
NATURE, vol. 382, 1996, pages 168
NATURE, vol. 396, 1998, pages 366
NORMAN ET AL., J. MED. CHEM., vol. 43, 2000, pages 4288 - 4312
PEPTIDES, vol. 11, 1990, pages 545
PEPTIDES, vol. 19, 1998, pages 359
PHARMACOLOGY & THERAPEUTICS, vol. 65, 1995, pages 397
PROCEEDING NATIONAL ACADEMIC SCIENCE USA, vol. 96, 1999, pages 13518
PROCEEDING NATIONAL ACADEMIC SCIENCE USA, vol. 97, 2000, pages 1595
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 84, 1987, pages 7413
REIDEMEISTER, S. ET AL., PHARMAZIE, vol. 55, 2000, pages 83 - 6
SASSE, A. ET AL., ARCH. PHARM.(WEINHEIM), vol. 334, 2001, pages 45 - 52
SASSE, A. ET AL., J. MED. CHEM., vol. 43, 2000, pages 3335 - 43
SYNAPSE, vol. 2, 1988, pages 299
TATEMOTO ET AL., NATURE, vol. 296, 1982, pages 659
THE JOURNAL OF ALLERGY AND IMMUNOLOGY, vol. 101, 1998, pages S345
THE JOURNAL OF NEUROSCIENCE, vol. 18, 1998, pages 3014
THE JOURNAL OF NEUROSCIENCE, vol. 21, 2001, pages 5367
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 244, 1988, pages 468
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 258, 1991, pages 633
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 261, 1992, pages 863
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 284, 1998, pages 633
TRENDS IN NEUROSCIENCE, vol. 20, 1997, pages 294
TRENDS IN PHARMACOLOGICAL SCIENCE, vol. 15, 1994, pages 153
TRENDS IN PHARMACOLOGICAL SCIENCE, vol. 20, 1999, pages 104

Cited By (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7589096B2 (en) 2002-11-29 2009-09-15 Banyu Pharmaceutical Co., Ltd. Azole derivatives
US7365079B2 (en) * 2002-11-29 2008-04-29 Banyu Pharmaceutical Co., Ltd. Azole derivatives
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US7960384B2 (en) 2006-03-28 2011-06-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
EP2698157A1 (en) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US8084605B2 (en) 2006-11-29 2011-12-27 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
WO2008120653A1 (ja) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. インドールジオン誘導体
US8318762B2 (en) 2008-05-28 2012-11-27 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
WO2010051236A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
WO2010099527A1 (en) 2009-02-27 2010-09-02 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8288405B2 (en) 2009-11-10 2012-10-16 Pfizer Inc. N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
US8507681B2 (en) 2009-11-10 2013-08-13 Pfizer Inc. N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
US9139587B2 (en) 2009-11-10 2015-09-22 Pfizer Inc. N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
US8802690B2 (en) 2009-11-10 2014-08-12 Pfizer Inc. N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
CN102762567A (zh) * 2009-12-21 2012-10-31 诺瓦提斯公司 作为食欲肽受体拮抗剂的二氮杂-螺[5.5]十一烷类
WO2011076747A1 (en) * 2009-12-21 2011-06-30 Novartis Ag Diaza-spiro[5.5]undecanes as orexin receptor antagonists
WO2011124520A1 (en) 2010-04-07 2011-10-13 Altachem Nv High performance valve
EP2374731A1 (en) 2010-04-07 2011-10-12 Altachem N.V. High performance valve
US9908883B2 (en) 2010-09-30 2018-03-06 Pfizer Inc. N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
US11673890B2 (en) 2010-09-30 2023-06-13 Pfizer Inc. N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
US8859577B2 (en) 2010-09-30 2014-10-14 Pfizer Inc. N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
US10822335B2 (en) 2010-09-30 2020-11-03 Pfizer Inc. N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
US10294225B2 (en) 2010-09-30 2019-05-21 Pfizer Inc. N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
US9145416B2 (en) 2010-09-30 2015-09-29 Pfizer Inc. N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
US8993586B2 (en) 2010-10-29 2015-03-31 Pfizer Inc. N1/N2-lactam acetyl-CoA carboxylase inhibitors
US9181252B2 (en) 2010-10-29 2015-11-10 Pfizer Inc. N1/N2-lactam acetyl-CoA carboxylase inhibitors
US8859773B2 (en) 2010-10-29 2014-10-14 Pfizer Inc. N1/N2-lactam acetyl-CoA carboxylase inhibitors
US10213427B2 (en) 2010-12-22 2019-02-26 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US10813930B2 (en) 2010-12-22 2020-10-27 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US8802688B2 (en) 2011-04-22 2014-08-12 Pfizer Inc. Substituted acetyl-coa carboxylase inhibitors
JPWO2013011932A1 (ja) * 2011-07-15 2015-02-23 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有するアザベンズイミダゾール誘導体
US10093670B2 (en) 2011-07-15 2018-10-09 Shionogi & Co., Ltd. Azabenzimidazole derivative having AMPK-activating activity
US9567330B2 (en) 2011-07-15 2017-02-14 Shionogi & Co., Ltd. Azabenzimidazole derivative having AMPK-activating activity
WO2013059222A1 (en) 2011-10-19 2013-04-25 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-nitrile orexin receptor antagonists
US11840534B2 (en) 2012-06-13 2023-12-12 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US11053246B2 (en) 2012-06-13 2021-07-06 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US10131667B2 (en) 2012-06-13 2018-11-20 Incyte Corporation Substituted tricyclic compounds as FGFR inhibitors
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US9745311B2 (en) 2012-08-10 2017-08-29 Incyte Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US11530214B2 (en) 2013-04-19 2022-12-20 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10947230B2 (en) 2013-04-19 2021-03-16 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US10040790B2 (en) 2013-04-19 2018-08-07 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10450313B2 (en) 2013-04-19 2019-10-22 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9890156B2 (en) 2015-02-20 2018-02-13 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11667635B2 (en) 2015-02-20 2023-06-06 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11173162B2 (en) 2015-02-20 2021-11-16 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10251892B2 (en) 2015-02-20 2019-04-09 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10738048B2 (en) 2015-02-20 2020-08-11 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10214528B2 (en) 2015-02-20 2019-02-26 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US11014923B2 (en) 2015-02-20 2021-05-25 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10016438B2 (en) 2015-02-20 2018-07-10 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9708318B2 (en) 2015-02-20 2017-07-18 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10632126B2 (en) 2015-02-20 2020-04-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9801889B2 (en) 2015-02-20 2017-10-31 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10611762B2 (en) 2017-05-26 2020-04-07 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US11472801B2 (en) 2017-05-26 2022-10-18 Incyte Corporation Crystalline forms of a FGFR inhibitor and processes for preparing the same
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11407750B2 (en) 2019-12-04 2022-08-09 Incyte Corporation Derivatives of an FGFR inhibitor
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2022040070A1 (en) 2020-08-18 2022-02-24 Merck Sharp & Dohme Corp. Bicycloheptane pyrrolidine orexin receptor agonists
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Also Published As

Publication number Publication date
CA2490722C (en) 2012-05-01
US7687514B2 (en) 2010-03-30
EP1517908B1 (en) 2011-04-20
US20060205750A1 (en) 2006-09-14
DOP2003000662A (es) 2003-12-30
EA200500103A1 (ru) 2005-06-30
AR040271A1 (es) 2005-03-23
IS7667A (is) 2005-01-27
CN1668615A (zh) 2005-09-14
WO2004002986A3 (en) 2004-04-22
ZA200409339B (en) 2006-02-22
NO20050184L (no) 2005-01-12
US20100048600A1 (en) 2010-02-25
CN100560585C (zh) 2009-11-18
BR0312066A (pt) 2005-03-29
EP1517908A2 (en) 2005-03-30
US7803807B2 (en) 2010-09-28
CN1955178A (zh) 2007-05-02
AU2003248248A1 (en) 2004-01-19
CA2490722A1 (en) 2004-01-08
PE20040583A1 (es) 2004-10-04
IL165810A0 (en) 2006-01-15
CN100427486C (zh) 2008-10-22
DE60336811D1 (de) 2011-06-01
ECSP045505A (es) 2005-03-10
MXPA04012731A (es) 2005-03-23
RS113704A (en) 2007-02-05
ATE506360T1 (de) 2011-05-15
AU2003248248B2 (en) 2009-03-12
US7105526B2 (en) 2006-09-12
TW200406411A (en) 2004-05-01
HRP20041218A2 (en) 2005-04-30
PL374693A1 (en) 2005-10-31
US20040054177A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
US7803807B2 (en) Benzimidazole derivatives
US7691860B2 (en) Sulfonamide derivatives
US7589096B2 (en) Azole derivatives
EP1546133B1 (en) N-substituted-2-oxodihydropyridine derivatives as npy antagonists
JP4496722B2 (ja) 新規ベンズイミダゾール誘導体
KR20050024422A (ko) 신규 벤즈이미다졸 유도체
EP2424860A1 (en) Heteroarylthiomethyl pyridine derivative

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-1137/04

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AU AZ BA BB BR BY BZ CA CN CO CR CU DM DZ EC GD GH HR ID IL IN IS JP KG KR KZ LC LK LR LT LV MA MD MG MK MN MX NI NO NZ OM PG PH PL RU SC SG SY TJ TM TN TT UA US UZ VC VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004/09339

Country of ref document: ZA

Ref document number: 1200401224

Country of ref document: VN

Ref document number: 200409339

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2003761822

Country of ref document: EP

Ref document number: 2003248248

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 536922

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1893/KOLNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 01893/KOLNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/A/2004/012731

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 165810

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2490722

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1-2004-502116

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 374693

Country of ref document: PL

Ref document number: P20041218A

Country of ref document: HR

Ref document number: 1020047021438

Country of ref document: KR

Ref document number: 20038153432

Country of ref document: CN

ENP Entry into the national phase

Ref country code: GE

Ref document number: GE P

WWE Wipo information: entry into national phase

Ref document number: 8603

Country of ref document: GE

Ref document number: 200500103

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 20050030

Country of ref document: UZ

WWP Wipo information: published in national office

Ref document number: 1020047021438

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003761822

Country of ref document: EP